SpHb Sensor MLNCS® Finger Multiple Users Reusable No cord

Features

• MLNCS Rainbow Sensors are only compatible with MLNCS Patient Cables. Please ensure current use of MLNCS Trunk Cables before purchasing this product.
• Masimo noninvasive hemoglobin (SpHb) sensors provide MORE than conventional pulse oximetry. They feature clinically proven Masimo SET measure through motion and low perfusion pulse oximetry while simultaneously providing the unique capability for spot-check noninvasive hemoglobin (SpHb) measurements from the same reusable finger sensor.
• Noninvasive hemoglobin measurements are provided in a timely manner and minimize patient discomfort due to no venipuncture or finger prick required. This also comes with the added benefit of no risk of exposure to bloodborne pathogens.
• Masimo SET Pulse Oximetry has been shown to have unrivaled accuracy and reliability in more than 100 clinical studies. It is the primary pulse oximetry at all top 10 U.S. hospitals (as of 2024) and monitors more than 200 million patients a year globally.
• Accurate During Motion. Before Masimo SET® pulse oximetry, false alarm rates were high, often due to motion and low perfusion. With Masimo SET®, the rate of false alarms dropped by more than 80% and yet true alarm detection improved significantly.
• Accurate During Low Perfusion. A recent peer-reviewed study found that for Masimo SET® SpO2, ARMS* accuracy was 1.37% in all subjects with normal perfusion and 1.64% in all subjects with low perfusion
• Accurate on All Skin Tones. A peer-reviewed publication demonstrated that Masimo RD SET sensors had only a 0.15% difference in bias between dark- and light-skinned subjects, which is not clinically significant because pulse oximeters only measure in whole numbers. Further analysis showed that RD SET accurately measured SpO2 for both Black and White subjects not only when perfusion was normal but also during low perfusion.
• Masimo SET® saves lives. A study conducted over 10 years on general floor patients being monitored with Masimo SET® while recovering from surgery found zero preventable deaths or brain damage from opioid-induced respiratory depression. Another study has shown that use of SET® led to an 80% reduction in the rate of retinopathy of prematurity (ROP, an eye disorder that can cause blindness in premature babies). Of particular note, in multiple studies, involving more than 300,000 newborns, use of SET® as part of screening for critical congenital heart disease (CCHD) has been shown to significantly improve screening sensitivity.